ciprofloxacin has been researched along with hr 810 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Carattoli, A; Ellington, MJ; Karisik, E; Livermore, DM; Underwood, A; Woodford, N | 1 |
| Ichiishi, S; Mikamo, H; Nakao, K; Shibata, T; Tanaka, K; Watanabe, K | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 1 |
| Anderson, KC; Kellogg, GE; Sarkar, A | 1 |
| Allard, S; Auger, F; Bisson, C; Daviau, N; Drapeau, C; LeBel, M; Paradis, D; Vallée, F | 1 |
| Boothman, C; King, A; Phillips, I | 1 |
| Bartmann, K; Tarbuc, R | 1 |
| Butzler, JP; Coignau, H; De Mol, P; Ghysels, G; Goossens, H; Grados, O; Innocent, H; Levy, J | 1 |
| Alvarez, ME; Bodey, GP; Hsu, KC; Rolston, KV | 1 |
| Appelbaum, PC; Sollenberger, L; Spangler, SK | 1 |
| Elkhaïli, H; Jehl, F; Kamili, N; Linger, L; Monteil, H; Pompei, D | 1 |
| Edouard, AR; Incagnoli, P; Jacolot, A; Mimoz, O; Petitjean, O; Samii, K; Tod, M | 1 |
| Doumith, M; Ellington, MJ; Hornsey, M; Hudson, S; Livermore, DM; Woodford, N | 1 |
14 other study(ies) available for ciprofloxacin and hr 810
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
Topics: beta-Lactamases; Computational Biology; Escherichia coli; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Plasmids; United Kingdom | 2009 |
Susceptibilities of 23 Desulfovibrio isolates from humans.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Clindamycin; Desulfovibrio; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2009 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics | 2012 |
Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
Topics: Adult; Cefpirome; Ceftazidime; Ceftriaxone; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Half-Life; Humans; Imipenem; Male; Microbial Sensitivity Tests | 1992 |
Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins.
Topics: Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Gentamicins; Microbial Sensitivity Tests | 1990 |
Comparative determination of minimal inhibitory and bactericidal concentrations of ciprofloxacin, cefotaxime and HR 810 for gram-negative bacteria either sensitive or resistant to ureidopenicillins and/or gentamicin.
Topics: Anti-Bacterial Agents; Cefotaxime; Cefpirome; Cephalosporins; Ciprofloxacin; Gentamicins; Gram-Negative Bacteria; Microbial Sensitivity Tests; Piperacillin; Quinolines | 1985 |
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.
Topics: Anti-Bacterial Agents; Aztreonam; Cefpirome; Cephalosporins; Ciprofloxacin; Enterobacteriaceae; Leucomycins; Microbial Sensitivity Tests; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1985 |
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
Topics: Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Ciprofloxacin; Cross Infection; Fluoroquinolones; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Neoplasms; Quinolines; Thienamycins | 1986 |
Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.
Topics: Anti-Infective Agents; Cefpirome; Cephalosporins; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin; Quinolines | 1986 |
[Kinetics of bactericidal activity of cefepime and cefpirome alone or combined with gentamicin, amikacin or ciprofloxacin against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacter cloacae hyperproductive in cephalosporinase].
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cefpirome; Cephalosporinase; Cephalosporins; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enterobacter cloacae; Gentamicins; In Vitro Techniques; Xanthomonas | 1996 |
Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
Topics: Adult; Anti-Infective Agents; Case-Control Studies; Cefpirome; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Statistics, Nonparametric; Systemic Inflammatory Response Syndrome; Wounds and Injuries | 1999 |
Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biological Transport, Active; Cefpirome; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacterial; Gene Deletion; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Minocycline; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Selection, Genetic; Serratia Infections; Serratia marcescens; Tigecycline; Up-Regulation | 2010 |